Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.44 USD | +4.55% | +3.78% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 401M | |
-2.44% | 103B | |
+1.74% | 95.28B | |
+1.46% | 22.15B | |
-15.77% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.04% | 16.05B | |
+5.34% | 13.68B | |
+34.35% | 12.17B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- William Blair Starts LENZ Therapeutics With Outperform Rating